手机版 English 帮助中心
外文文献知网节
文献信息节点
基本信息 摘要 关键词 核心评价 相关文献
Journal | [J] 医学研究 Volume 5, Issue 19. 2023.
贝伐珠单抗治疗复发高级别胶质瘤的研究进展
作者 : 靳 云泽
DOI: 10.12361/2661-3603-05-19-146729
全部来源
获取全文
摘要 / Abstract
摘要：高级别胶质瘤是一种恶性程度高、易复发、预后差的中枢神经系统恶性肿瘤，而手术合并术后Ｓｔｕｐｐ方案的治疗效果却并不能令人满意。以血管内皮生长因子为靶点的贝伐珠单抗具有抑制血管生长的功能，己经被美国食品药品监督管理局（ＦＤＡ）批准用于高级别胶质瘤的治疗。近年来，开展了许多有关贝伐珠单抗联合其他治疗手段治疗高级别胶质瘤的临床研究，但对于联合用药的疗效、模式及安全性尚存有较多争议。本文现就贝伐珠单抗的作用机制及贝伐珠单抗单药与联合化疗或其他药物在高级别脑胶质瘤中的应用进展进行综述，以期为临床上使用贝伐珠单抗治疗高级别胶质瘤提供参考。
关键词 / Keywords
关键词：高级别胶质瘤；贝伐珠单抗；复发；治疗；安全性
Related articles / 相关文献
相似文献
作者发文
机构发文
关键词分析
相似文献（说明：与本文内容较接近的文献）
  • [ii]Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report:primary brain and central nervous system tumors diagnosedin the UnitedStates in 2005-2009[J]. Neuro Oncol, 2012, 14(Suppl5):1-49.[iii]hmidt MH, Berger MS, LambornKR, et al . Repeated operationsforinfiltrativelow-grade gliomas withoutintervening therapy[J].J Neurosurg 03,98(6):1165-1169.[iiv]l-Gil MJ, Mesia C, Rey M, et al .Bevacizumab for the treatmentofglioblastoma[J]. Clin Med InsightsOncol , 2013(7):123-135.[v]汪洋,盛晓芳,高晶,等.高分级神经胶质瘤 112 例术后放、化疗疗效及其预后分析【J】.肿瘤，2009,29（7）:668-672.[vi]Jo J, Schiff D, Purow B. Angiogenic inhibition in high-grade gliomas:past, present and future[J]. Expert Rev Neurother, 2012, 12(6):733-747.[vii]Liu Y, Zhou Y, Zhang XS, et al. Expression of VEGF and MMP-9andMRI imaging changes in cerebral glioma[J]. Oncol Lett, 2011, 2(6):1171-1175[viii]FolkmanJ.Tumorangiogensis:roleinreg ulationoftumorgrowth[J].Sy mpSocD evB i ol,974,30(0):43-52.[ix] 李扬,胡欣,程刚,等.贝伐单抗在中国晚期恶性肿瘤受试者中的药动学研究[J].中国药学杂志,2010,45(22):1749-1752.[x]LuJF,Bruno R, Eppler S, et al. Clinical pharmacokineticsofbevacizumab in patients with solid tumors[J]. Cancer Chemother Pharma⁃col,2008, 62(5):779-786.[xi]陈辉,蒋传路.贝伐单抗治疗高级别脑胶质瘤研究进 M[J].哈尔滨医 科 大 学 报 ,2014,48(3):260-262.DO丨:10.3969/j.issn.1000-8179.20130842.[xii]Hacibekiroglu I, Kodaz H, ErdoganB, et al . Single-agentbevacizumabis an effective treatment in recurrentglioblastoma[J], Med Oncol ,2015,32(2):460.[xiii]Kreisl TN, Zhang W, Odia Y, et al.A Phase II trial ofsingle-agentbevacizumab in patients with recurrentanaplastic glioma[J]. NeuroOncol, 2011,13(10):1143-1150.[xiv]Nagane M, Nishikawa R, Narita Y, et al. Phase II study ofsingle-agent bevacizumab n Japanese patients with recurrent malignantglioma[J]. Jpn J Clin Oncol, 2012, 42(10):887-895.[xv]Wong ET,Gautam S,Malchow C,et al.Bevacizumab forrecurrentglioblastoma multiforme:a Meta-analysis[J]. J Natl ComprCancNetw, 2011, 9(4): 403-407.[xvi] Perry JR, Bélanger K, Mason WP, et al. Phase II trialofcontinuousdose-intense temozolomide in recurrentmalignant glioma: RESCUEstudy[J]. JClin Oncol, 2010, 28(12):2051-2057.[xvii] Murray LJ, Bridgewater CH, Levy D. Carboplatin chemotherapyinpatients with recurrent high-grade glioma[J]. Clin Oncol(R Coll Radiol),2011, 23(1):55-61.[xviii]Desjardins A, Reardon DA, Coan A, et al. Bevacizumab anddailytemozolomide for recurrent glioblastoma[J]. Cancer, 2012, 118(5):1302-1312.[xix] Mathieu V, De Nève N, Le Mercier M, et al. Combiningbevacizumab with temozolomide increases the antitumor efficacy oftemozolomide in a human glioblastoma orthotopic xenograft model[J].Neoplasia, 2008, 10(12):1383-1392.[xx]Lai A, Tran A, Nghiemphu PL, et al. Phase II study ofbevacizumabplus temozolomide during and after radiation therapy forpatientswith newly diagnosed glioblastoma multiforme[J]. J Clin Oncol,2011,29(2):142-148.[xxi] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapyplusconcomitant and adjuvant temozolomide for glioblastoma[J]. NEngl J Med,2005, 352(10):987-996.[xxi]Narayana A, Gruber D, Kunnakkat S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma[J]. JNeurosurg,2012,116(2):341-345.[xxii]陆云涛,漆松涛,欧阳辉,等.贝伐株单抗治疗国人复发恶性胶质瘤的初步临床分析与评估 [J]. 中国医学杂志 , 2014,94(15):1165-1168.[xxiii]Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone andincombination withirinotecan in recurrent glioblastoma[J]. J ClinOncol, 2009,27(28):4733-4740.[xxiv] Gil MJ, de Las Peñas R, Reynés G, et al. Bevacizumab plusirinotecan in recurrent malignant glioma shows high overall survival inamulticenter retrospective pooled series of the Spanish Neuro-OncologyResearch Group(GEINO)[J]. Anticancer Drugs, 2012, 23(6):659-665.[xxv] Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumabaloneand in combination with irinotecan in the treatment of patients with recurrentglioblastoma multiforme[J]. J Clin Neurosci,2012, 19(12):1636-1640.[xxvi] mirci U, Tufan G, Aktas B, et al .Bevacizumab plus irinotecanincurrent or progressive malignglioma: a multicenter study of theAnatolianSociety of Medical Oncology(ASMO)[J]. J Cancer Res Clin Oncol,2013, 139(5):829-835.[xxvii] Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growthfactor receptor, protein kinase B/Akt, and glioma response to erlotinib[J]. J NatlCancer Inst, 2005, 97(12):880-887.[xxviii] Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase IItrial of bevacizumab and erlotinib in patients with recurrent malignantglioma[J]. Neuro Oncol, 2010, 12(12):1300-1310.[xxix] Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomicchemotherapy with daily, oral etoposide plus bevacizumab for recurrentmalignant glioma: a phase II study[J]. Br J Cancer, 2009, 101(12):1986-1994.[xxx]Gutin PH, Iwamoto FM, Beal K, et al .Safety and efficacy ofbevacizumabwith hypofractionated stereotacticirradiationfor recurrent malignantgliomas[J]. Int J Radiat Oncol Biol Phys.2009, 75(1):156-163.[xxxi]Fileger M, Ganswindt U, Schwarz SB,et al . Re-irradiation andbevacizumabin recurrent high-grade glioma:an effective treatment option[J].Jurooncol , 2014, 117(2):337-345.[xxxii]Minniti G, Agolli L, Falco T, etal . Hypofractionated stereotacticradiotherapy in combination withbevacizumab or fotemustine forpatients withprogressive malignantgliomas[J]. JNeurooncol , 2015,2(3):559-566.[xxxiii]Seidel C, Hentschel B, Simon M, etal .A comprehensive analysisof vascularcomplications in 3,889 glioma patientsfrom the German GliomaNetwork[J]. J Neurol , 2013, 260(3):847-855.[xxxiv]Simonetti G, Trevisan E, SilvaniA, etal . Safety of bevacizumabinpatients with malignantgliomas: asystematic review[J] Neurol Sci ,2014,35(1):83-89.[xxxv]Taylor J, Gerstner ER. Anti-angiogenictherapy in high-gradeglioma(treatment and toxicity)[J]. Curr TreatOptions Neurol , 2013, 15(3):328-337.[xxxvi]Bag AK, Kim H, Gao Y, et al . Prolongedtreatment with bevacizumab isassociated with brain atrophy: apilot study in patients with high-gradegliomas[J]. J Neurooncol , 2015,22(3):585-593.[xxxvii]Clark AJ, Lamborn KR, Butowski NA,etal . Neurosurgical managementand prognosis of patients with glioblastoma that progresses duringbevacizumab treatment[J].Neurosurgery , 2012, 70(2):361-370[xxxviii]Zuniga RM,Torcuator R, Jain R, et al .Rebound tumourprogression afterthe cessation of bevacizumab therapyin patients withrecurrent high-grade glioma[J]. J Neurooncol , 2010,99(2):237-242.[xxxix]]Lu Y, Qi S, Ouyang H, et al . Preliminaryclinical evaluations ofbevacizumab forrecurrent malignant glioma in Chinesepatients[J]. ZhonghuaYixue Zazhi,2014, 94(15):1165-1168
《中国学术期刊(光盘版)》电子杂志社有限公司 KDN平台基础技术由KBASE 11.0提供
© 2014-2018中国知网(CNKI) 京公网安备11010802020460号 经营性网站备案信息 互联网出版许可证 新出网证(京)字271号 京ICP证040431号